HOUSTON, Feb. 20, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications,
today announced that its President and Chief Executive
Officer, Peter L. Hoang, and Chief
Development Officer, Dr. Juan F.
Vera, will be presenting at the CAR-TCR Summit Europe, which
is being held in London, UK
from February 25-27.
Presentation Details
Title: "Current Strategies to Reduce Cost of Manufacture"
Speaker: Dr. Juan F. Vera
Date: Tuesday, February 26, 2019
Time: 12:15 p.m. GMT
Panel Discussion: "Explore the Need to Reduce the Cost of
Manufacturing in Order to Ensure Feasible Reimbursements"
Moderator: Peter L. Hoang
Date: Tuesday, February 26, 2019
Time: 4:15 p.m. GMT
Title: "Innovative Antigen Screening Methods"
Speaker: Peter L. Hoang
Date: Wednesday, February 27,
2019
Time: 2:00 p.m. GMT
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. Once infused into patients,
this population of T cells attacks multiple tumor targets and acts
to activate the patient's immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cells, when compared to current engineered CAR-T and
TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly
less toxic, and (iii) are associated with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling therapeutic product profile, as compared
to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase II clinical
trials. In parallel, we are developing a proprietary DNA expression
technology named PolyStart™ that can enhance the ability of the
immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement Disclaimer
This release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our
non-engineered multi-tumor antigen specific T cell therapies; our
TPIV200 and TPIV100/110 programs and our PolyStart™ program; the
effectiveness of these programs or the possible range of
application and potential curative effects and safety in the
treatment of diseases; and, the timing and success of our clinical
trials, as well as multi-tumor antigen specific T cell clinical
trials conducted by our collaborators. Forward-looking statements
are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from
those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-car-tcr-summit-europe-300798301.html
SOURCE Marker Therapeutics, Inc.